NDC product
Naproxen and esomeprazole magnesium
NDC 85509-1202 · PHOENIX RX LLC
Key facts
| Product NDC | 85509-1202 |
|---|---|
| Proprietary name | Naproxen and esomeprazole magnesium |
| Nonproprietary name | Naproxen and esomeprazole magnesium |
| Substances | NAPROXEN, ESOMEPRAZOLE MAGNESIUM |
| Dosage form | TABLET, DELAYED RELEASE |
| Route | ORAL |
| Labeler | PHOENIX RX LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA213699 |
| Pharmacologic classes | Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC], Proton Pump Inhibitor [EPC] and 1 more |
| Marketing start | Oct 6, 2022 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: